BACKGROUND: Without diagnosis and antiviral therapy, many patients with chronic hepatitis C infections will develop end-stage liver disease and die from complications. AIMS: To evaluate the future impacts of preventive interventions and treatment advances, this paper forecasts a baseline estimate of the future morbidity and mortality of prevalent hepatitis C when left untreated. METHODS: We simulated the future disease progression and death for all Americans with prevalent hepatitis C in 2005. To validate the model, we used past seroprevalence to forecast contemporary outcomes. We used the validated model to forecast future cases of end-stage liver disease, transplants, and deaths from 2010 to 2060, and we estimated credible intervals using Monte Carlo simulation. RESULTS: When programmed with past data, our model predicted current levels of hepatitis C outcomes with accuracy between ±1% and 13%. Morbidity and mortality from hepatitis C will rise from 2010 to a peak between the years 2030 and 2035. We forecasted a peak of 38,600 incident cases of end-stage liver disease; 3200 referrals for transplant; and 36,100 deaths. CONCLUSIONS: Because current rates of screening and treatment are low, future morbidity and mortality from hepatitis C are likely to increase substantially without public health interventions to increase treatment.
BACKGROUND: Without diagnosis and antiviral therapy, many patients with chronic hepatitis C infections will develop end-stage liver disease and die from complications. AIMS: To evaluate the future impacts of preventive interventions and treatment advances, this paper forecasts a baseline estimate of the future morbidity and mortality of prevalent hepatitis C when left untreated. METHODS: We simulated the future disease progression and death for all Americans with prevalent hepatitis C in 2005. To validate the model, we used past seroprevalence to forecast contemporary outcomes. We used the validated model to forecast future cases of end-stage liver disease, transplants, and deaths from 2010 to 2060, and we estimated credible intervals using Monte Carlo simulation. RESULTS: When programmed with past data, our model predicted current levels of hepatitis C outcomes with accuracy between ±1% and 13%. Morbidity and mortality from hepatitis C will rise from 2010 to a peak between the years 2030 and 2035. We forecasted a peak of 38,600 incident cases of end-stage liver disease; 3200 referrals for transplant; and 36,100 deaths. CONCLUSIONS: Because current rates of screening and treatment are low, future morbidity and mortality from hepatitis C are likely to increase substantially without public health interventions to increase treatment.
Authors: Daniel John Smyth; Duncan Webster; Lisa Barrett; Mark MacMillan; Lisa McKnight; Frank Schweiger Journal: Can J Gastroenterol Hepatol Date: 2014-11
Authors: Anne F Peery; Seth D Crockett; Alfred S Barritt; Evan S Dellon; Swathi Eluri; Lisa M Gangarosa; Elizabeth T Jensen; Jennifer L Lund; Sarina Pasricha; Thomas Runge; Monica Schmidt; Nicholas J Shaheen; Robert S Sandler Journal: Gastroenterology Date: 2015-08-29 Impact factor: 22.682
Authors: Lesley S Miller; Francois Rollin; Shelly-Ann Fluker; Kristina L Lundberg; Brandi Park; Kristi Quairoli; Nyiramugisha K Niyibizi; Anne C Spaulding Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Amy Jewett; Arika Garg; Katherine Meyer; Laura Danielle Wagner; Katherine Krauskopf; Kimberly A Brown; Jen-Jung Pan; Omar Massoud; Bryce D Smith; David B Rein Journal: Health Promot Pract Date: 2014-04-28
Authors: Rositsa B Dimova; Marija Zeremski; Ira M Jacobson; Holly Hagan; Don C Des Jarlais; Andrew H Talal Journal: Clin Infect Dis Date: 2012-12-07 Impact factor: 9.079
Authors: A Blythe Ryerson; Christie R Eheman; Sean F Altekruse; John W Ward; Ahmedin Jemal; Recinda L Sherman; S Jane Henley; Deborah Holtzman; Andrew Lake; Anne-Michelle Noone; Robert N Anderson; Jiemin Ma; Kathleen N Ly; Kathleen A Cronin; Lynne Penberthy; Betsy A Kohler Journal: Cancer Date: 2016-03-09 Impact factor: 6.860